Browsing by Author "Uğur K."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Evaluating individual differences in patients with major depressive disorder focused on nine types temperament model; [Major depresif bozukluk tanılı hastaların bireysel farklılıkları üzerine dokuz tip mizaç modeli odaklı bir inceleme]
    (ANP Publishing, 2020) Üstündağ M.F.; Yılmaz E.D.; Uğur K.; Ünal Ö.; Herdem A.; Aydın O.; Aydemir Ö.
    Objective: The aim of this study is to investigate the relationship of Major Depressive Disorder (MDD) and MDD specifiers with temperament and personality traits with a perspective focused on Nine Type Temperament Model (NTTM). Method: 203 healthy participants who are matched with the 208 MDD participants group between 18-60 years old and in at least eight weeks remission period and treatment in progress, without an additional diagnosis were included in the study. Socio-demographic data form, Nine Types of Temperament Scale (NTTS) and Temperament Character Inventory (TCI) were applied to all participants, and in addition, Hamilton Depression Rating Scale (HDRS) were applied to the subjects with MDD. MDD specifiers were evaluated using follow-up data files. Results: According to results, both Nine Type Temperament (NTT) Model’s types, which are NTT1, NTT2, NTT3, NTT4, NTT6 and NTT8, and Psychobiological Personality Model’s dimensions which are consisted of the cooperation, persistence, harm avoidance and self-management were found to be associated with MDD. From the point of MDD determinants; anxiety-distressing characteristics are associated with NTM2, NTM3, NTM6, NTM9; melancholy characteristics is concerned with NTT1, NTT5 and NTT6; seasonal characteristics are related to NTT4; mixed features are relevant with NTT4 and NTT7; and atypical features are associated with NTT5, NTT7, NTT9. As a result, MDD determinants are found to be associated with temperament types which are coming from NTTM. Discussion: It is seen that temperament, which constitutes the structural basis of personality, is an effective parameter both in the diagnosis and in the individual-specific recognition of symptomatology in MDD patients. In addition, it can be said that temperament can be a discriminating factor in defining MDD specifiers. The development of temperament-oriented diagnosis and treatment strategies in future studies may be beneficial for the practice. © 2020 ANP Publishing. All rights reserved.
  • No Thumbnail Available
    Item
    Biochemical characteristics and calcium and PTH levels of patients with high normal and elevated serum 25(OH)D levels in Turkey: DeVIT-TOX survey
    (Springer Science and Business Media Deutschland GmbH, 2021) Pekkolay Z.; Yavuz D.G.; Saygılı E.S.; Değertekin C.K.; Topaloğlu Ö.; Önder Ç.E.; Soylu H.; Taskaldıran I.; Pazır A.E.; Uğur K.; Tanrıkulu S.; Fırat S.N.; Atak B.M.; Batman A.; Omma T.; Cağıltay E.; Özdemir N.; Altuntaş S.Ç.; İmga N.N.; Karakılıç E.; Hekimsoy Z.; Kılınç F.; Yay A.; Eroğlu M.; Tuzcu A.K.
    Summary: Vitamin D intake over the recommended dose is usually associated with high serum 25(OH)D levels and generally not associated with symptoms of hypercalcemia. High doses of cholecalciferol need to be avoided to protect against vitamin D toxicity and related complications. Strict adherence to the clinical guidelines for treating vitamin D deficiency can ensure safe and effective treatment. Purpose: We observed a tendency to use high doses of cholecalciferol for vitamin D deficiency treatment or vitamin D supplementation. We aimed to determine the biochemical characteristics of patients with high normal and elevated serum 25(OH)D levels. Methods: An online invitation was sent to all tertiary endocrinology clinics in Turkey to complete an online retrospective survey (DeVIT-TOX Survey) for patients diagnosed with high serum 25(OH)D levels (> 88 ng/mL) between January 2019 and December 2019. The patients were evaluated according to the presence of signs and symptoms of hypercalcemia and doses of vitamin D intake, evaluated into the following three groups according to their 25(OH)D levels: group 1, > 150 ng/mL; group 2, 149–100 ng/mL; and group 3, 99–88 ng/mL. Results: A total of 253 patients were included in the final analysis (female/male: 215/38; mean age, 51.5 ± 15.6 years). The average serum 25(OH)D level was 119.9 ± 33 (range, 88–455) ng/mL, and the average serum calcium level was 9.8 ± 0.7 (range, 8.1–13.1) mg/dL. Most (n = 201; 75.4%) patients were asymptomatic despite having high serum 25(OH)D and calcium levels. The serum 25(OH)D level was significantly higher in the symptomatic groups than in the asymptomatic groups (138.6 ± 64 ng/mL vs. 117.7 ± 31 ng/mL, p < 0.05). The most common cause (73.5%) associated with high serum 25(OH)D levels was the inappropriate prescription of a high dose of oral vitamin D (600.000–1.500.000 IU) for treating vitamin D deficiency/insufficiency in a short time (1–3 months). The cut-off value of 25 (OH) D level in patients with hypercalcemia was found to be 89 ng/mL [median 116.5 (89–216)]. Conclusions: High dose of vitamin D intake is associated with a high serum 25 OH D level, without symptoms of hypercalcemia. Inappropriate prescription of vitamin D is the primary cause for elevated 25(OH) D levels and related hypercalcemia. Hypercalcemia may not be observed in every patient at very high 25(OH) D levels. Adherence to the recommendation of guidelines is essential to ensure safe and effective treatment of vitamin D deficiency. © 2021, International Osteoporosis Foundation and National Osteoporosis Foundation.